Within the cancer cohort (Table 1), GAS6 expression is significantly higher in tumours from patients with residual disease (defined as those with observable lesions greater than 10 mm in size) than those without (P = 0.0156) (Figure 2(a)). Here, GAS6 is linked to neoplasm.